JPWO2023284559A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023284559A5 JPWO2023284559A5 JP2024502055A JP2024502055A JPWO2023284559A5 JP WO2023284559 A5 JPWO2023284559 A5 JP WO2023284559A5 JP 2024502055 A JP2024502055 A JP 2024502055A JP 2024502055 A JP2024502055 A JP 2024502055A JP WO2023284559 A5 JPWO2023284559 A5 JP WO2023284559A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- nucleotide
- seq
- sirna
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110807464 | 2021-07-16 | ||
| CN202110807464.3 | 2021-07-16 | ||
| PCT/CN2022/103049 WO2023284559A1 (zh) | 2021-07-16 | 2022-06-30 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024525800A JP2024525800A (ja) | 2024-07-12 |
| JP2024525800A5 JP2024525800A5 (https=) | 2025-07-03 |
| JPWO2023284559A5 true JPWO2023284559A5 (https=) | 2025-07-03 |
Family
ID=84919019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024502055A Pending JP2024525800A (ja) | 2021-07-16 | 2022-06-30 | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240325428A1 (https=) |
| EP (1) | EP4372085A4 (https=) |
| JP (1) | JP2024525800A (https=) |
| KR (1) | KR20240034787A (https=) |
| CN (2) | CN117580953B (https=) |
| AU (1) | AU2022309416A1 (https=) |
| CA (1) | CA3225015A1 (https=) |
| MX (1) | MX2024000650A (https=) |
| TW (1) | TW202321450A (https=) |
| WO (1) | WO2023284559A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025520796A (ja) * | 2022-06-27 | 2025-07-03 | 大睿生物 | アポリポタンパク質Ｃ３発現を阻害するｓｉＲＮＡ |
| WO2024188174A1 (zh) * | 2023-03-10 | 2024-09-19 | 苏州瑞博生物技术股份有限公司 | 一种药物组合物及其用途 |
| TW202508607A (zh) * | 2023-05-19 | 2025-03-01 | 大陸商北京炫景瑞醫藥科技有限公司 | 雙股寡核苷酸及其共軛物和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| CA2750561C (en) * | 2009-01-26 | 2017-10-10 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein c-iii expression |
| US20120136073A1 (en) | 2010-11-15 | 2012-05-31 | Life Technologies Corporation | Amine-Containing Transfection Reagents and methods for making and using same |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| EP3564374A1 (en) * | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| JP6702862B2 (ja) | 2013-07-11 | 2020-06-03 | アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オリゴヌクレオチド−リガンドコンジュゲートおよびそれらの調製方法 |
| EP3052627B1 (en) * | 2013-10-04 | 2018-08-22 | Novartis AG | Novel formats for organic compounds for use in rna interference |
| WO2015168661A1 (en) * | 2014-05-01 | 2015-11-05 | Smith Larry J | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT |
| EP3736334A1 (en) * | 2014-07-16 | 2020-11-11 | Arrowhead Pharmaceuticals, Inc. | Rnai compositions to treat apoc3-related diseases |
| JP2018511555A (ja) * | 2015-02-27 | 2018-04-26 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | リポジストロフィー集団におけるアポリポタンパク質Ｃ−ＩＩＩ（ＡｐｏＣＩＩＩ）発現の調節 |
| JP2020522265A (ja) * | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| US10597657B2 (en) * | 2017-09-11 | 2020-03-24 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
| CA3083968C (en) | 2017-12-01 | 2024-04-23 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
| JP7365052B2 (ja) * | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| EP3732185B1 (en) | 2017-12-29 | 2025-02-26 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| US12496347B2 (en) * | 2018-12-28 | 2025-12-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| WO2021067744A1 (en) * | 2019-10-02 | 2021-04-08 | Dicerna Pharmaceuticals, Inc. | Chemical modifications of small interfering rna with minimal fluorine content |
| CN112876534B (zh) * | 2019-11-29 | 2024-02-09 | 苏州瑞博生物技术股份有限公司 | 肝靶向化合物及缀合物 |
-
2022
- 2022-06-30 CN CN202280046072.2A patent/CN117580953B/zh active Active
- 2022-06-30 EP EP22841197.1A patent/EP4372085A4/en active Pending
- 2022-06-30 CN CN202511150352.XA patent/CN120989078A/zh active Pending
- 2022-06-30 MX MX2024000650A patent/MX2024000650A/es unknown
- 2022-06-30 CA CA3225015A patent/CA3225015A1/en active Pending
- 2022-06-30 WO PCT/CN2022/103049 patent/WO2023284559A1/zh not_active Ceased
- 2022-06-30 KR KR1020247004393A patent/KR20240034787A/ko active Pending
- 2022-06-30 US US18/576,563 patent/US20240325428A1/en active Pending
- 2022-06-30 AU AU2022309416A patent/AU2022309416A1/en active Pending
- 2022-06-30 JP JP2024502055A patent/JP2024525800A/ja active Pending
- 2022-07-15 TW TW111126698A patent/TW202321450A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019214587A5 (https=) | ||
| JPWO2021030778A5 (https=) | ||
| CN115698288A (zh) | 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途 | |
| CN121079412A (zh) | 经修饰的指导rna | |
| AU2020391215A1 (en) | Methods of synthesizing RNA molecules | |
| JPWO2023284763A5 (https=) | ||
| JP2026500220A (ja) | 高度ｒｎａ標的化（ａｒｎａｔａｒ） | |
| JP7793144B2 (ja) | 修飾ヘテロ核酸 | |
| BR112021001756A2 (pt) | oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção | |
| JP2025541721A (ja) | 化学修飾アンチセンスオリゴヌクレオチド（ａｓｏ）およびそれを含むｒｎａ編集のための組成物 | |
| JPWO2023284559A5 (https=) | ||
| CN120118909B (zh) | 靶向调控LPA基因表达的siRNA双链体及其在预防和治疗心脑血管相关疾病中的用途 | |
| JP2002523335A (ja) | Ｖｅｇｆ発現の抑制のためのアンチセンスオリゴヌクレオチド | |
| US20250376684A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| US20240336920A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JPWO2021087036A5 (https=) | ||
| JPWO2023041508A5 (https=) | ||
| JP7813254B2 (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| RU2024103826A (ru) | Нуклеиновая кислота, композиция и конъюгат, содержащие ее, а также способ ее получения и применение | |
| TW202309286A (zh) | 作為新穎基因靜默技術的非對稱短雙股ｄｎａ及其應用 | |
| TW202313977A (zh) | 作為新穎基因靜默技術的短雙股ｄｎａ及其應用 | |
| EP4150084A1 (en) | Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same | |
| JP2022521510A (ja) | ホスホノアセテートギャップマー型オリゴヌクレオチド | |
| JPWO2023116607A5 (https=) | ||
| KR102138495B1 (ko) | 이중 가닥의 올리고뉴클레오티드 및 그 제조 방법 |